As of 2025-05-21, the EV/EBITDA ratio of Korea Arlico Pharm Co Ltd (260660.KQ) is
63.57.
EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 260660.KQ's latest enterprise value
is 149,334.70 mil KRW. 260660.KQ's TTM EBITDA according to its financial statements is
2,348.96 mil KRW. Dividing these 2
quantities gives us the above 260660.KQ EV/EBITDA ratio.
|
Range |
Selected |
| Trailing P/E multiples |
7.5x - 16.7x |
10.1x |
| Forward P/E multiples |
7.2x - 10.4x |
9.9x |
| Fair Price |
(1,126.01) - 7,489.29 |
3,125.08 |
| Upside |
-115.1% - 0.4% |
-58.1% |